Aaron Gardner, Robert Yeh, Nathan Ajiashvili, Salvatore Vanchieri, Matthew DeSilva
January 24, 2026
Latham & Watkins Advises Zentalis in Exclusive License With Immunome for ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
1 min
AI-made summary
- Immunome, Inc
- and Zentalis Pharmaceuticals, Inc
- have entered into an exclusive, worldwide license agreement in which Immunome has licensed ZPC-21, a preclinical ROR1 antibody-drug conjugate, and Zentalis’ proprietary ADC platform technology from Zentalis
- ZPC-21 is expected to be submitted for IND in the first quarter of 2025
- Latham & Watkins LLP advised Zentalis on the transaction with a team led by several New York and San Diego partners and associates.
Immunome, Inc. (Nasdaq: IMNM) and Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), have announced that they have entered into an exclusive, worldwide license agreement under which Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug conjugate (ADC) with best-in-class potential on track for IND submission in 1Q 2025, and Zentalis’ proprietary ADC platform technology. Latham & Watkins LLP advised Zentalis in the transaction with a licensing team led by New York partner Aaron Gardner, with San Diego associate Robert Yeh, and a corporate team led by New York partners Nathan Ajiashvili and Salvatore Vanchieri, with associate Matthew DeSilva.~~
Article Author
Aaron Gardner, Robert Yeh, Nathan Ajiashvili, Salvatore Vanchieri, Matthew DeSilva
The Sponsor